#United States #San Diego #Hexagon #Inhibrx #INBRX-106

Inhibrx Webcast to Unveil Clinical Insights on INBRX-106 Study

Inhibrx Biosciences, Inc., a leading player in the biopharmaceutical realm, is set to host a live webcast presentation on May 11, 2026, at 5:30 AM Pacific Time. This presentation will provide a crucial update on the interim results from the HexAgon study, which is analyzing the potential of INBRX-106 in the treatment of first-line head and neck squamous cell carcinoma (HNSCC).

The HexAgon study is a randomized Phase 2 trial that evaluates the safety and efficacy of INBRX-106, a hexavalent agonist targeting the OX40 receptor. This innovative treatment approach combines INBRX-106 with pembrolizumab, a well-known PD-1 inhibitor, and pits this combination therapy against pembrolizumab monotherapy in patients with PD-L1 positive metastatic or unresectable recurrent HNSCC.

What is INBRX-106?

INBRX-106 is designed using Inhibrx's proprietary single-domain antibody platform. This unique approach facilitates high-order receptor clustering, which is essential for robust T-cell activation and longevity—something that traditional bivalent antibody methods have struggled to achieve. By focusing on the OX40 receptor, INBRX-106 aims to enhance the immune response against tumors, particularly in challenging cases of head and neck cancers.

How to Participate

Interested investors and media representatives can join the webcast through the following link: Webcast Link or by calling (1-888-880-3330). When connecting via phone, please ensure to reference Inhibrx or use the conference ID 1841482. For those unable to attend live, a recording of the presentation will be accessible in the